Zhou et al. showed that a combination treatment of a WNT/β-catenin signaling inhibitor with Nilotinib synergistically killed KBM5T315I cells (a CML resistant cell line) as well as primary BC-CML cells obtained from TKI-resistant patients (with and without BCR-ABL1 kinase mutations) by decreasing the expression of CD44, MYC, p-CRKL, p-STAT5, and survivin [129]. The gene discussed is CRKL; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.